Citations

Showing 10 of 108104 citations.

Evaluation of BCG Vaccination and Plasma Amyloid: A Prospective, Pilot Study with Implications for Alzheimer’s Disease
Dow, Coad Thomas , Greenblatt, Charles L. , Chan, Edward D. , Dow, Jordan, Dow, Jordan F

Mayo Clinic

Microorganisms | February 13, 2022 | Volume: 10 | Issue: 2 | Pages: 424

10.3390/microorganisms10020424 | PMID 35208878 Get It

BCG vaccine has been used for 100 years to prevent tuberculosis. Not all countries, including the United States, adopted the initial World Health Organization recommendation to use BCG. Moreover, many Western countries that had routinely used BCG have discontinued its use. Recent population studies demonstrate lower prevalence of Alzheimer’s disease (AD) in countries with high BCG coverage. Intravesicular instillation of BCG is also used to treat bladder cancer that has not invaded the bladder muscle wall and has been shown to reduce recurrence. Several retrospective studies of bladder cancer patients demonstrated that BCG treatment was associated with a significantly reduced risk of developing AD. Plasma amyloid β assessment has become a fertile area of study for an AD biomarker that is predictive of a positive amyloid PET scan. Mass spectrometry-based plasma amyloid 42/40 ratio has proven to be accurate and robust, and when combined with age and ApoE, is shown to accurately predict current and future brain amyloid status. These parameters, amyloid 42/40 ratio, age and ApoE genotype are incorporated into an Amyloid Probability Score (APS)–a score that identifies low, intermediate or high risk of having a PET scan positive for cerebral amyloid. Community recruitment was used for this open-label pilot study. Forty-nine BCG-naïve, immunocompetent individuals completed our study: prior to BCG prime and boost, as determined by the APS, 34 had low risk (APS 0–35), 5 had intermediate risk (APS 36–57) and 10 had high risk (APS 58–100). The APS range for the participant group was 0 to 94. Follow-up plasma amyloid testing 9 months after vaccination revealed a reduction in the APS in all the risk groups: low risk group (p = 0. 37), intermediate risk group (p = 0.13) and the high-risk group (statistically significant, p = 0.016). Greater benefit was seen in younger participants and those with the highest risk. The small number of participants and the nascent status of plasma amyloid testing will rightfully temper embracement of these results. However, both the favorable direction of change after BCG as well as the utility of the APS—a valuable surrogate AD biomarker—may prompt a definitive large-scale multicenter investigation of BCG and AD risk as determined by plasma amyloid peptide ratios and APS.
Pheochromocytomas and Abdominal Paragangliomas: A Practical Guidance
Juhlin, C. Christofer , Bancos, Irina , Falhammar, Henrik , Juhlin, Carl Christofer , Bancos, Irina , Falhammar, Henrik , Calissendorff, Jan

Mayo Clinic

Cancers | February 13, 2022 | Volume: 14 | Issue: 4 | Pages: 917

10.3390/cancers14040917 | PMID 35205664 Get It

Pheochromocytomas and abdominal paragangliomas (PPGLs) are rare tumors arising from the adrenal medulla or the sympathetic nervous system. This review presents a practical guidance for clinicians dealing with PPGLs. The incidence of PPGLs has risen. Most cases are detected via imaging and less present with symptoms of catecholamine excess. Most PPGLs secrete catecholamines, with diffuse symptoms. Diagnosis is made by imaging and tests of catecholamines. Localized disease can be cured by surgery. PPGLs are the most heritable of all human tumors, and germline variants are found in approximately 30–50% of cases. Such variants can give information regarding the risk of developing recurrence or metastases as well as the risk of developing other tumors and may identify relatives at risk for disease. All PPGLs harbor malignant potential, and current histological and immunohistochemical algorithms can aid in the identification of indolent vs. aggressive tumors. While most patients with metastatic PPGL have slowly progressive disease, a proportion of patients present with an aggressive course, highlighting the need for more effective therapies in these cases. We conclude that PPGLs are rare but increasing in incidence and management should be guided by a multidisciplinary team.
Equitable Mindfulness: The practice of mindfulness for all
Bautista, Tara G. , Cash, Tiara A. , Meyerhoefer, Terence, Pipe, Teri , G Bautista, Tara

Mayo Clinic

Journal of Community Psychology | February 12, 2022 | Volume: 50 | Issue: 7 | Pages: 3141-3155

10.1002/jcop.22821 | PMID 35150593 Get It

Abstract The benefits of mindfulness are well‐documented; however, these benefits may not be evenly distributed across communities. Equitable Mindfulness aims to make these benefits accessible to a wider and more inclusive audience. The aim of this study was to investigate the applicability of Equitable Mindfulness and systemic barriers that prevent mindfulness programs from being equitably accessed across communities. Twenty‐one participants were recruited for qualitative in‐depth interviews during a 2‐day mindfulness conference. The constant comparison method was used to iteratively identify and categorize themes that emerged within and across interviews. Five dominant themes emerged from the data as follows: inherent equitability, accessibility, inclusiveness, awareness and knowledge‐sharing, and acknowledgement of multiple perspectives. Having an applicable and meaningful term to use when describing mindfulness as an inclusive and equitable practice can facilitate the exploration of a new area of research. There is a need for future initiatives aimed at making mindfulness trainings and programs more equitable and accessible to all, regardless of socioeconomic status, race/ethnicity, or abilities/disabilities.
Anti‐Neuronal Nuclear Antibody 3 Autoimmunity Targets Dachshund Homolog 1
Ζεκερίδου, Αναστασία , Yang, Binxia , Lennon, Vanda A. , Guo, Yong , Lucchinetti, Claudia F. , McKeon, Andrew , Pittock, Sean J. , Zekeridou, Anastasia , Wu, Liang, McKeon, Andrew , Pittock, S J , Yang, Binxia , Wu, Liang Li , Flanagan, Eoin P.

Mayo Clinic

Annals of Neurology | February 12, 2022 | Volume: 91 | Issue: 5 | Pages: 670-675

10.1002/ana.26320 | PMID 35150165 Get It

The antigen specificity of Anti‐Neuronal Nuclear Antibody‐type 3 (ANNA3)‐IgG is unknown. We identified Dachshund‐homolog 1 (DACH1) as the ANNA3 autoantigen and confirmed it by antigen‐specific assays, immunohistochemical colocalization and immune absorption experiments. Patients' median age was 63.5 years (range, 49–88); 67% were female. Neurological manifestations (information available for 30 patients) included one or more of neuropathy, 12; cognitive difficulties, 11; ataxia, 8; dysautonomia, 7. Evidence of a neoplasm was present in 27 of 30 (90%), most of neuroendocrine lineage. DACH1‐IgG is rare and represents a novel proposed biomarker of neurological autoimmunity and cancer. ANN NEUROL 2022;91:670–675
Sclerotherapy for Hereditary Hemorrhagic Telangiectasia-Related Epistaxis: A Systematic Review
Thiele, Brittney , Abdel‐Aty, Yassmeen , Marks, Lisa , Marino, Michael J. , Marino, Michael J , Marks, Lisa A , Thiele, Brittney , Lal, Devyani

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | February 12, 2022 | Volume: 132 | Issue: 1 | Pages: 82-90

10.1177/00034894221078075 | PMID 35152768 Get It

Objectives: Hereditary hemorrhagic telangiectasia (HHT) is a common inherited condition characterized by mucosal telangiectasias, recurrent epistaxis, and arteriovenous malformations. HHT results in detriment to quality of life. Morbidity and mortality result from severe anemia. Conventional interventions for HHT-related epistaxis include nasal packing, diathermy, lasers, coblation, microdebridement, bevacizumab (topical and systemic), as well as septodermoplasty and nasal closure. Sclerotherapy has been recently described in the literature as a novel approach to HHT-related epistaxis. We hypothesize that sclerotherapy is an effective treatment for HHT-related epistaxis and improves upon the current standard of care for this disease. Methods: A systematic review was conducted to study sclerotherapy for treating HHT-related epistaxis. Ovid MEDLINE, Ovid EMBASE, Scopus, and Web of Science were searched. Articles were evaluated and excluded according to PRISMA guidelines and reviewed by 2 authors. Reported variables included number of injections, months of follow up, changes in Epistaxis Severity Score, previous treatments used to control epistaxis, and post-injection side effects. Results: Seven studies with a total of 196 patients met inclusion criteria. Three studies reported significant improvement as measured by the Epistaxis Severity Score scale. One reported improvement through subjective patient surveys and others used the Bergler-Sadick scale to measure frequency and intensity of epistaxis. All studies reported improvement in HHT-related epistaxis. The lack of uniform reporting measures however precluded formal meta-analysis. Conclusions: Based on limited data, sclerotherapy appears to be effective for treating HHT-related epistaxis and offers promise for treating this recalcitrant condition. However, larger, prospective, multi-centered studies using universally validated instruments for epistaxis are needed to definitively evaluate outcomes from sclerotherapy.
Interstitial Optical Monitoring of Focal Laser Ablation
Geoghegan, Rory , Zhang, Le , Priester, Alan , Wu, Holden H. , Marks, Leonard, Natarajan, Shyam, Wu, Holden H , Geoghegan, Rory , Zhang, Le , Priester, Alan , Marks, Leonard, Natarajan, Shyam

Mayo Clinic

IEEE Transactions on Biomedical Engineering | February 12, 2022 | Volume: 69 | Issue: 8 | Pages: 2545-2556

10.1109/tbme.2022.3150279 | PMID 35148260 Get It

Resident Rotation Scheduling for Categorical Internal Medicine Residency Program
Wang, Feifan , Huang, Yu-Li , Ju, Feng , Grega, Jaimie C., Wang, Feifan

Mayo Clinic

IEEE Robotics and Automation Letters | February 12, 2022 | Volume: 7 | Issue: 2 | Pages: 4142-4148

10.1109/lra.2022.3150515 Get It

Lectures on Radiation Dosimety Physics
Kissick, M, Fakhraei, Sharareh

Mayo Clinic

No container title available | February 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.54947/9781930524927 Get It

This book is based on course notes from Medical Physics 501, a quite famous course in the Medical Physics Department of the University of Wisconsin–Madison. All of this material derives very heavily from Frank "Herb" Attix, the course's original instructor. It also benefited from Thomas Rockwell Mackie, the course's second instructor, who innovated by more properly organizing the material. From Alireza Kassaee in Medical Physics…"I find the Lectures on Radiation Dosimetry Physics a well mathematically illustrated supplemental book for a graduate course in radiation dosimetry. It is also a fine reference for practicing medical physicists who are using the two dosimetry protocols and need to either remind themselves of fundamentals or have a deeper understanding of the details in the protocols without having to refer to many publications and textbooks on the subject." Modern protocols can guide a person toward uncertainties of only 0.5% in the energy deposited per unit mass, the dose. In order to achieve this remarkably low level of uncertainty, one must fully understand all of the subtleties along the way. That is the purpose of this book. This book covers essential physics concepts for understanding and calculating problems in the physical energy deposited in matter from ionizing radiation. The focus of application is on medical uses, both imaging and radiation therapy. There is more weight on radiation therapy throughout the book because of the much greater need for accuracy and precision in that field. This work also draws upon many others, including Paul DeLuca and others in the University of Wisconsin–Madison medical physics and human oncology departments. Also helpful were many of the faculty of the nuclear engineering departments of both Pennsylvania State University and the University of Wisconsin–Madison.
Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin α6β1 drives endocrine resistance in breast cancer cells
Espinoza, Ingrid, Yang, Lin , Steen, Travis Vander, Vellón, Luciano , Verdura, Sara , Lau, Lester F. , Menéndez, Javier A. , Lupu, Ruth , Verdura, Sara , Menendez, Javier A , Espinoza, Ingrid , Cuyàs, Elisabet

Mayo Clinic

Aging | February 11, 2022 | Volume: 14 | Issue: 3 | Pages: 1200-1213

10.18632/aging.203882 | PMID 35148282 Get It